Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CME vs NDAQ

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CME
CME Group Inc.

Financial - Data & Stock Exchanges

Financial ServicesNASDAQ • US
Market Cap$104.06B
5Y Perf.+57.1%
NDAQ
Nasdaq, Inc.

Financial - Data & Stock Exchanges

Financial ServicesNASDAQ • US
Market Cap$50.59B
5Y Perf.+125.4%

CME vs NDAQ — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CME logoCME
NDAQ logoNDAQ
IndustryFinancial - Data & Stock ExchangesFinancial - Data & Stock Exchanges
Market Cap$104.06B$50.59B
Revenue (TTM)$6.52B$8.22B
Net Income (TTM)$4.24B$1.91B
Gross Margin86.1%47.9%
Operating Margin64.9%28.4%
Forward P/E23.5x22.6x
Total Debt$3.76B$9.93B
Cash & Equiv.$4.42B$814M

CME vs NDAQLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CME
NDAQ
StockMay 20May 26Return
CME Group Inc. (CME)100157.1+57.1%
Nasdaq, Inc. (NDAQ)100225.4+125.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: CME vs NDAQ

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: NDAQ leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. CME Group Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CME
CME Group Inc.
The Banking Pick

CME is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 6 yrs, beta -0.30, yield 3.8%
  • Lower volatility, beta -0.30, Low D/E 13.1%, current ratio 92.97x
  • PEG 1.71 vs NDAQ's 2.12
Best for: income & stability and sleep-well-at-night
NDAQ
Nasdaq, Inc.
The Banking Pick

NDAQ carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 11.1%, EPS growth 60.1%
  • 356.8% 10Y total return vs CME's 289.3%
  • 11.1% NII/revenue growth vs CME's 6.4%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNDAQ logoNDAQ11.1% NII/revenue growth vs CME's 6.4%
ValueCME logoCMEPEG 1.71 vs 2.12
Quality / MarginsNDAQ logoNDAQEfficiency ratio 0.2% vs CME's 0.2% (lower = leaner)
Stability / SafetyCME logoCMELower D/E ratio (13.1% vs 81.2%)
DividendsCME logoCME3.8% yield, 6-year raise streak, vs NDAQ's 1.2%
Momentum (1Y)NDAQ logoNDAQ+15.2% vs CME's +5.5%
Efficiency (ROA)NDAQ logoNDAQEfficiency ratio 0.2% vs CME's 0.2%

CME vs NDAQ — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CMECME Group Inc.
FY 2025
clearing and transaction fees
81.0%$5.3B
MarketData
12.3%$803M
OtherRevenue
6.7%$436M
NDAQNasdaq, Inc.
FY 2025
Market Services
51.4%$4.2B
Capital Access Platforms
26.1%$2.1B
Market Technology
22.6%$1.9B

CME vs NDAQ — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCMELAGGINGNDAQ

Income & Cash Flow (Last 12 Months)

CME leads this category, winning 4 of 5 comparable metrics.

NDAQ and CME operate at a comparable scale, with $8.2B and $6.5B in trailing revenue. CME is the more profitable business, keeping 62.0% of every revenue dollar as net income compared to NDAQ's 21.8%.

MetricCME logoCMECME Group Inc.NDAQ logoNDAQNasdaq, Inc.
RevenueTrailing 12 months$6.5B$8.2B
EBITDAEarnings before interest/tax$4.7B$3.1B
Net IncomeAfter-tax profit$4.2B$1.9B
Free Cash FlowCash after capex$4.4B$2.0B
Gross MarginGross profit ÷ Revenue+86.1%+47.9%
Operating MarginEBIT ÷ Revenue+64.9%+28.4%
Net MarginNet income ÷ Revenue+62.0%+21.8%
FCF MarginFCF ÷ Revenue+64.3%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+21.4%+33.8%
CME leads this category, winning 4 of 5 comparable metrics.

Valuation Metrics

CME leads this category, winning 4 of 7 comparable metrics.

At 25.7x trailing earnings, CME trades at a 11% valuation discount to NDAQ's 28.8x P/E. Adjusting for growth (PEG ratio), CME offers better value at 1.87x vs NDAQ's 2.70x — a lower PEG means you pay less per unit of expected earnings growth.

MetricCME logoCMECME Group Inc.NDAQ logoNDAQNasdaq, Inc.
Market CapShares × price$104.1B$50.6B
Enterprise ValueMkt cap + debt − cash$103.4B$59.7B
Trailing P/EPrice ÷ TTM EPS25.70x28.80x
Forward P/EPrice ÷ next-FY EPS est.23.49x22.65x
PEG RatioP/E ÷ EPS growth rate1.87x2.70x
EV / EBITDAEnterprise value multiple22.95x20.14x
Price / SalesMarket cap ÷ Revenue15.96x6.16x
Price / BookPrice ÷ Book value/share3.60x4.19x
Price / FCFMarket cap ÷ FCF24.81x25.44x
CME leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

CME leads this category, winning 5 of 9 comparable metrics.

NDAQ delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $15 for CME. CME carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to NDAQ's 0.81x. On the Piotroski fundamental quality scale (0–9), NDAQ scores 9/9 vs CME's 5/9, reflecting strong financial health.

MetricCME logoCMECME Group Inc.NDAQ logoNDAQNasdaq, Inc.
ROE (TTM)Return on equity+15.3%+15.9%
ROA (TTM)Return on assets+2.2%+6.4%
ROICReturn on invested capital+10.2%+8.1%
ROCEReturn on capital employed+3.6%+10.2%
Piotroski ScoreFundamental quality 0–959
Debt / EquityFinancial leverage0.13x0.81x
Net DebtTotal debt minus cash-$666M$9.1B
Cash & Equiv.Liquid assets$4.4B$814M
Total DebtShort + long-term debt$3.8B$9.9B
Interest CoverageEBIT ÷ Interest expense41.55x14.11x
CME leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — CME and NDAQ each lead in 3 of 6 comparable metrics.

A $10,000 investment in NDAQ five years ago would be worth $17,139 today (with dividends reinvested), compared to $16,437 for CME. Over the past 12 months, NDAQ leads with a +15.2% total return vs CME's +5.5%. The 3-year compound annual growth rate (CAGR) favors CME at 19.8% vs NDAQ's 18.7% — a key indicator of consistent wealth creation.

MetricCME logoCMECME Group Inc.NDAQ logoNDAQNasdaq, Inc.
YTD ReturnYear-to-date+9.1%-7.6%
1-Year ReturnPast 12 months+5.5%+15.2%
3-Year ReturnCumulative with dividends+71.9%+67.4%
5-Year ReturnCumulative with dividends+64.4%+71.4%
10-Year ReturnCumulative with dividends+289.3%+356.8%
CAGR (3Y)Annualised 3-year return+19.8%+18.7%
Evenly matched — CME and NDAQ each lead in 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CME and NDAQ each lead in 1 of 2 comparable metrics.

CME is the less volatile stock with a -0.30 beta — it tends to amplify market swings less than NDAQ's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricCME logoCMECME Group Inc.NDAQ logoNDAQNasdaq, Inc.
Beta (5Y)Sensitivity to S&P 500-0.30x0.78x
52-Week HighHighest price in past year$329.16$101.79
52-Week LowLowest price in past year$257.17$77.09
% of 52W HighCurrent price vs 52-week peak+87.1%+87.4%
RSI (14)Momentum oscillator 0–10046.061.4
Avg Volume (50D)Average daily shares traded2.2M3.3M
Evenly matched — CME and NDAQ each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CME and NDAQ each lead in 1 of 2 comparable metrics.

Wall Street rates CME as "Hold" and NDAQ as "Buy". Consensus price targets imply 28.8% upside for NDAQ (target: $115) vs 11.7% for CME (target: $320). For income investors, CME offers the higher dividend yield at 3.81% vs NDAQ's 1.17%.

MetricCME logoCMECME Group Inc.NDAQ logoNDAQNasdaq, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$320.25$114.60
# AnalystsCovering analysts3536
Dividend YieldAnnual dividend ÷ price+3.8%+1.2%
Dividend StreakConsecutive years of raises613
Dividend / ShareAnnual DPS$10.92$1.04
Buyback YieldShare repurchases ÷ mkt cap+0.3%+1.2%
Evenly matched — CME and NDAQ each lead in 1 of 2 comparable metrics.
Key Takeaway

CME leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 3 categories are tied.

Best OverallCME Group Inc. (CME)Leads 3 of 6 categories
Loading custom metrics...

CME vs NDAQ: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is CME or NDAQ a better buy right now?

For growth investors, Nasdaq, Inc.

(NDAQ) is the stronger pick with 11. 1% revenue growth year-over-year, versus 6. 4% for CME Group Inc. (CME). CME Group Inc. (CME) offers the better valuation at 25. 7x trailing P/E (23. 5x forward), making it the more compelling value choice. Analysts rate Nasdaq, Inc. (NDAQ) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CME or NDAQ?

On trailing P/E, CME Group Inc.

(CME) is the cheapest at 25. 7x versus Nasdaq, Inc. at 28. 8x. On forward P/E, Nasdaq, Inc. is actually cheaper at 22. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CME Group Inc. wins at 1. 71x versus Nasdaq, Inc. 's 2. 12x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — CME or NDAQ?

Over the past 5 years, Nasdaq, Inc.

(NDAQ) delivered a total return of +71. 4%, compared to +64. 4% for CME Group Inc. (CME). Over 10 years, the gap is even starker: NDAQ returned +356. 8% versus CME's +289. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CME or NDAQ?

By beta (market sensitivity over 5 years), CME Group Inc.

(CME) is the lower-risk stock at -0. 30β versus Nasdaq, Inc. 's 0. 78β — meaning NDAQ is approximately -358% more volatile than CME relative to the S&P 500. On balance sheet safety, CME Group Inc. (CME) carries a lower debt/equity ratio of 13% versus 81% for Nasdaq, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — CME or NDAQ?

By revenue growth (latest reported year), Nasdaq, Inc.

(NDAQ) is pulling ahead at 11. 1% versus 6. 4% for CME Group Inc. (CME). On earnings-per-share growth, the picture is similar: Nasdaq, Inc. grew EPS 60. 1% year-over-year, compared to 15. 4% for CME Group Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CME or NDAQ?

CME Group Inc.

(CME) is the more profitable company, earning 62. 0% net margin versus 21. 8% for Nasdaq, Inc. — meaning it keeps 62. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CME leads at 64. 9% versus 28. 4% for NDAQ. At the gross margin level — before operating expenses — CME leads at 86. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CME or NDAQ more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, CME Group Inc. (CME) is the more undervalued stock at a PEG of 1. 71x versus Nasdaq, Inc. 's 2. 12x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Nasdaq, Inc. (NDAQ) trades at 22. 6x forward P/E versus 23. 5x for CME Group Inc. — 0. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NDAQ: 28. 8% to $114. 60.

08

Which pays a better dividend — CME or NDAQ?

All stocks in this comparison pay dividends.

CME Group Inc. (CME) offers the highest yield at 3. 8%, versus 1. 2% for Nasdaq, Inc. (NDAQ).

09

Is CME or NDAQ better for a retirement portfolio?

For long-horizon retirement investors, CME Group Inc.

(CME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 30), 3. 8% yield, +289. 3% 10Y return). Both have compounded well over 10 years (CME: +289. 3%, NDAQ: +356. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CME and NDAQ?

Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CME is a mid-cap income-oriented stock; NDAQ is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CME

Dividend Mega-Cap Quality

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 37%
Run This Screen
Stocks Like

NDAQ

Quality Mega-Cap Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 13%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CME and NDAQ on the metrics below

Revenue Growth>
%
(CME: 6.4% · NDAQ: 11.1%)
Net Margin>
%
(CME: 62.0% · NDAQ: 21.8%)
P/E Ratio<
x
(CME: 25.7x · NDAQ: 28.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.